{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-276373","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.600221+00:00","generated_at":"2026-06-22T08:38:26.063366+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kura Oncology secures $25M equity from BMS and up to $125M debt from Hercules; runway into 2026","bullets":["Bristol Myers Squibb invests $25M at $18.25/share for 1.37M shares; BMS appoints member to Global Steering Committee.","Hercules Capital provides up to $125M term loan; $10M drawn immediately, $15M available at Kura’s discretion.","Additional $75M in two tranches upon clinical milestones; fourth $25M tranche subject to Hercules approval.","Loan bears 8.65% interest; interest-only for 24 months extendable to 48 months; matures Nov 2027.","Proceeds from both transactions, if fully drawn, extend cash runway into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-276373","json":"https://secwatch.observer/filing/0001193125-22-276373.json","markdown":"https://secwatch.observer/filing/0001193125-22-276373.md","text":"https://secwatch.observer/filing/0001193125-22-276373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/0001193125-22-276373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/d408638d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:38:26.063366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9ca567fa2c248cec3012f4865ac9ac2faf456798","claim":"Kura Oncology, Inc. incurred term loan of up to $125.0 million with Hercules Capital, Inc. at the greater of (i) the prime rate as reported in The Wall Street Journal minus 6 maturing the fifth anniversary of the Effective Date.","evidence_excerpt":"the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date, (ii) two additional tranches of term loans in the amounts of up to $35.0 million (the “Tranche 2 Loan”) and $40.0 million (the “Tranche 3 Loan”), respectively, which will become available to the Company upon the Company’s satisfaction of certain terms and conditions set forth in the Loan Agreement, and (iii) a final tranche of term","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/0001193125-22-276373-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"up to $125.0 million"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Rate","value":"the greater of (i) the prime rate as reported in The Wall Street Journal minus 6"},{"label":"Maturity","value":"the fifth anniversary of the Effective Date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"165aba09e5d244e00822ceb2396e8fd824a754e0","claim":"Kura Oncology, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at Up to $125.0 million in senior secured term loans, with initial $10.0 million funded immediately aft (effective 2022-11-02).","evidence_excerpt":"Also on November 2, 2022 (the “Effective Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”) and Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent and collateral agent for itself and the Lenders, pursuant to which the Lenders have agreed to make available to the Company up to $125.0 million in senior secured term loans (the “Term Loan Facility”), consisting of (i) an initial term loan of up to $25.0 million, $10.0 million of which was funded immediately after the Effective Date","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/0001193125-22-276373-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Value","value":"Up to $125.0 million in senior secured term loans, with initial $10.0 million funded immediately aft"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"material_agreement"},{"claim_id":"be9b075fa753b893ec64ab08d046fcb48a6ea07b","claim":"Kura Oncology, Inc. entered into Securities Purchase Agreement with Bristol-Myers Squibb Company valued at 1,370,171 shares of common stock at $18.2459 per share for gross proceeds of approximately $25.0 mil (effective 2022-11-02).","evidence_excerpt":"On November 2, 2022, Kura Oncology, Inc. (“Kura” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Bristol-Myers Squibb Company (“BMS”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000119312522276373/0001193125-22-276373-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Value","value":"1,370,171 shares of common stock at $18.2459 per share for gross proceeds of approximately $25.0 mil"},{"label":"Effective","value":"2022-11-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}